Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with or without chemotherapy in neoadjuvant HNSCC
NCT04807140Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jul 2021
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Sun Yat-sen Memorial Hospital. Started Jul 2021; status: recruiting.
02
Drugs
toripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04807140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04807140.